Literature DB >> 11200762

[Unusual course of a pulmonary artery catheter through a persistent superior vena cava] .

M Ould-Ahmed1, B Mas, E Hautbois, J F Garcia, P Caroff, M Guiavarch.   

Abstract

We report the unusual course of a pulmonary artery catheter through a persistent left-sided superior vena cava. After left subclavian vein cannulation and downward left-sided paramediastinum course, the Swan-Ganz catheter enters the right pulmonary artery. Haemodynamic monitoring was consistent with the diagnosis of septic shock developed by this 56-year-old woman, after cephalic duodenopancreatectomy. Persistent left-sided superior vena cava occurs in 0.5% of the population and 5-10% of patients with congenital heart diseases. It drains into the right atrium through the coronary sinus in 92% of cases and is associated with an absent right superior vena cava in 20% of cases. The left-sided superior vena cava persists when the caudal part of the left anterior cardinal vein does not degenerate. A persistent left superior vena cava may be medically relevant during implantation of pacemaker leads or radiofrequency ablation, during cardiac surgery for placement of a retrograde coronary sinus cardioplegia catheter and during transjugular intrahepatic portosystemic shunt placement.

Entities:  

Mesh:

Year:  2000        PMID: 11200762     DOI: 10.1016/s0750-7658(00)00319-1

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  2 in total

1.  Persistent left vena cava incidentally recognized during subclavian vein catheterization.

Authors:  Julien Bordes; Yves Asencio; Erwan d'Arranda; Philippe Goutorbe
Journal:  Crit Care       Date:  2010-02-15       Impact factor: 9.097

Review 2.  Persistent left superior vena cava: review of the literature, clinical implications, and relevance of alterations in thoracic central venous anatomy as pertaining to the general principles of central venous access device placement and venography in cancer patients.

Authors:  Stephen P Povoski; Hooman Khabiri
Journal:  World J Surg Oncol       Date:  2011-12-28       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.